(RMD) ResMed - Ratings and Ratios
CPAP, Ventilator, Diagnostic, Software, Cloud
RMD EPS (Earnings per Share)
RMD Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 37.5% |
| Value at Risk 5%th | 51.7% |
| Relative Tail Risk | -16.17% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.15 |
| Alpha | -10.64 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.486 |
| Beta | 0.638 |
| Beta Downside | 0.560 |
| Drawdowns 3y | |
|---|---|
| Max DD | 43.87% |
| Mean DD | 12.86% |
| Median DD | 9.22% |
Description: RMD ResMed September 29, 2025
ResMed Inc. (NYSE:RMD) designs, manufactures, and markets medical devices and cloud-based software for diagnosing, treating, and managing respiratory disorders worldwide, organized into two primary segments: Sleep & Breathing Health and Residential Care Software.
Its sleep-apnea portfolio includes the ApneaLink Air portable diagnostic unit, the disposable NightOwl device that estimates AHI via peripheral arterial tone and actigraphy, and the EasyCare Tx system for in-lab titration, all of which target clinics, hospitals, and home-care settings.
On the digital side, ResMed offers AirView-a remote-monitoring platform that lets clinicians adjust device settings over the cloud-myAir, a patient-facing app that drives therapy adherence, and a cellular connectivity module that links compatible ventilators to the AirView ecosystem.
Beyond respiratory care, the firm supplies Brightree, HEALTHCAREfirst, MatrixCare, and MEDIFOX DAN software suites that support home-medical-equipment providers, hospice and home-health agencies, skilled-nursing facilities, and senior-living operators, creating a diversified SaaS revenue stream.
Key metrics (FY 2023): total revenue $3.30 billion, up ~12 % YoY; operating margin 16 %; and recurring SaaS revenue now represents roughly 70 % of total sales, a trend that buffers the business against device-cycle volatility. The global sleep-apnea market is projected to grow at a 6 % CAGR through 2030, driven by aging demographics, rising obesity rates, and expanding tele-health reimbursement policies-factors that underpin ResMed’s growth outlook.
For a deeper, data-driven assessment of ResMed’s valuation and risk profile, you may find the analyst tools on ValueRay worth exploring.
RMD Stock Overview
| Market Cap in USD | 35,966m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1995-06-02 |
| Return 12m vs S&P 500 | -7.02% |
| Analyst Rating | 3.95 of 5 |
RMD Dividends
| Dividend Yield | 0.92% |
| Yield on Cost 5y | 1.09% |
| Yield CAGR 5y | 6.67% |
| Payout Consistency | 100.0% |
| Payout Ratio | 22.8% |
RMD Growth Ratios
| CAGR 3y | 3.89% |
| CAGR/Max DD Calmar Ratio | 0.09 |
| CAGR/Mean DD Pain Ratio | 0.30 |
| Current Volume | 1008.4k |
| Average Volume | 1214.3k |
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (1.44b TTM) > 0 and > 6% of Revenue (6% = 315.4m TTM) |
| FCFTA 0.21 (>2.0%) and ΔFCFTA 2.62pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 45.08% (prev 36.13%; Δ 8.95pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.23 (>3.0%) and CFO 1.88b > Net Income 1.44b (YES >=105%, WARN >=100%) |
| Net Debt (-537.5m) to EBITDA (1.98b) ratio: -0.27 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.89 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (147.0m) change vs 12m ago -0.38% (target <= -2.0% for YES) |
| Gross Margin 60.08% (prev 57.20%; Δ 2.88pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 67.70% (prev 66.56%; Δ 1.14pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 86.71 (EBITDA TTM 1.98b / Interest Expense TTM 20.1m) >= 6 (WARN >= 3) |
Altman Z'' 8.89
| (A) 0.29 = (Total Current Assets 3.63b - Total Current Liabilities 1.26b) / Total Assets 8.31b |
| (B) 0.76 = Retained Earnings (Balance) 6.34b / Total Assets 8.31b |
| (C) 0.22 = EBIT TTM 1.75b / Avg Total Assets 7.77b |
| (D) 2.87 = Book Value of Equity 6.28b / Total Liabilities 2.19b |
| Total Rating: 8.89 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 94.70
| 1. Piotroski 8.0pt = 3.0 |
| 2. FCF Yield 4.99% = 2.49 |
| 3. FCF Margin 33.61% = 7.50 |
| 4. Debt/Equity 0.14 = 2.49 |
| 5. Debt/Ebitda -0.27 = 2.50 |
| 6. ROIC - WACC (= 13.57)% = 12.50 |
| 7. RoE 25.13% = 2.09 |
| 8. Rev. Trend 97.71% = 7.33 |
| 9. EPS Trend 95.86% = 4.79 |
What is the price of RMD shares?
Over the past week, the price has changed by -2.56%, over one month by -9.27%, over three months by -13.94% and over the past year by +6.57%.
Is ResMed a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RMD is around 208.88 USD . This means that RMD is currently overvalued and has a potential downside of -14.55%.
Is RMD a buy, sell or hold?
- Strong Buy: 8
- Buy: 4
- Hold: 6
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the RMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 293.5 | 20% |
| Analysts Target Price | 293.5 | 20% |
| ValueRay Target Price | 232.3 | -5% |
RMD Fundamental Data Overview November 06, 2025
P/E Trailing = 25.2459
P/E Forward = 25.9067
P/S = 6.841
P/B = 6.7651
P/EG = 1.8635
Beta = 0.87
Revenue TTM = 5.26b USD
EBIT TTM = 1.75b USD
EBITDA TTM = 1.98b USD
Long Term Debt = 658.4m USD (from longTermDebt, last fiscal year)
Short Term Debt = 289.9m USD (from shortTermDebt, last quarter)
Debt = 846.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -537.5m USD (from netDebt column, last quarter)
Enterprise Value = 35.43b USD (35.97b + Debt 846.4m - CCE 1.38b)
Interest Coverage Ratio = 86.71 (Ebit TTM 1.75b / Interest Expense TTM 20.1m)
FCF Yield = 4.99% (FCF TTM 1.77b / Enterprise Value 35.43b)
FCF Margin = 33.61% (FCF TTM 1.77b / Revenue TTM 5.26b)
Net Margin = 27.35% (Net Income TTM 1.44b / Revenue TTM 5.26b)
Gross Margin = 60.08% ((Revenue TTM 5.26b - Cost of Revenue TTM 2.10b) / Revenue TTM)
Gross Margin QoQ = 61.46% (prev 60.84%)
Tobins Q-Ratio = 4.26 (Enterprise Value 35.43b / Total Assets 8.31b)
Interest Expense / Debt = 1.04% (Interest Expense 8.79m / Debt 846.4m)
Taxrate = 21.99% (98.3m / 446.8m)
NOPAT = 1.36b (EBIT 1.75b * (1 - 21.99%))
Current Ratio = 2.89 (Total Current Assets 3.63b / Total Current Liabilities 1.26b)
Debt / Equity = 0.14 (Debt 846.4m / totalStockholderEquity, last quarter 6.12b)
Debt / EBITDA = -0.27 (Net Debt -537.5m / EBITDA 1.98b)
Debt / FCF = -0.30 (Net Debt -537.5m / FCF TTM 1.77b)
Total Stockholder Equity = 5.72b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.31% (Net Income 1.44b / Total Assets 8.31b)
RoE = 25.13% (Net Income TTM 1.44b / Total Stockholder Equity 5.72b)
RoCE = 27.36% (EBIT 1.75b / Capital Employed (Equity 5.72b + L.T.Debt 658.4m))
RoIC = 21.75% (NOPAT 1.36b / Invested Capital 6.26b)
WACC = 8.19% (E(35.97b)/V(36.81b) * Re(8.36%) + D(846.4m)/V(36.81b) * Rd(1.04%) * (1-Tc(0.22)))
Discount Rate = 8.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.17%
[DCF Debug] Terminal Value 80.42% ; FCFE base≈1.60b ; Y1≈1.97b ; Y5≈3.37b
Fair Price DCF = 368.8 (DCF Value 53.83b / Shares Outstanding 146.0m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 95.86 | EPS CAGR: 16.89% | SUE: 0.52 | # QB: 0
Revenue Correlation: 97.71 | Revenue CAGR: 9.76% | SUE: 0.20 | # QB: 0
Additional Sources for RMD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle